Immunome (NASDAQ:IMNM) Director Philip Wagenheim Sells 28,200 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Philip Wagenheim sold 28,200 shares of Immunome stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $20.65, for a total value of $582,330.00. Following the transaction, the director owned 341,147 shares of the company’s stock, valued at $7,044,685.55. This trade represents a 7.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Philip Wagenheim also recently made the following trade(s):

• On Friday, March 20th, Philip Wagenheim sold 36,800 shares of Immunome stock. The shares were sold at an average price of $20.47, for a total value of $753,296.00.

Immunome Stock Up 3.7%

Shares of NASDAQ:IMNM opened at $20.75 on Tuesday. The business’s 50 day moving average is $22.76 and its 200 day moving average is $18.64. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $27.65. The stock has a market cap of $2.35 billion, a price-to-earnings ratio of -8.57 and a beta of 2.12.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. As a group, equities research analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IMNM. T. Rowe Price Investment Management Inc. grew its stake in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after acquiring an additional 2,823,144 shares in the last quarter. Primecap Management Co. CA boosted its holdings in shares of Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. bought a new position in shares of Immunome in the fourth quarter worth $30,710,000. Finally, Sofinnova Investments Inc. grew its position in shares of Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after purchasing an additional 1,182,426 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on IMNM shares. Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Immunome in a research note on Thursday, January 15th. Lake Street Capital upped their target price on Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Guggenheim lifted their price target on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, HC Wainwright began coverage on Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 price objective on the stock. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.45.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.